James Crosby retweeted
Delighted to share that the 𝐉𝐨𝐮𝐫𝐧𝐚𝐥 𝐨𝐟 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐄𝐜𝐨𝐧𝐨𝐦𝐢𝐜𝐬 is partnered with the 𝐖𝐨𝐫𝐥𝐝 𝐄𝐏𝐀 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 in 2025. To discover more about the conference use the link below 👇
terrapinn.com/epa/IJME
#healtheconomics #medicaleconomics #HEOR #RWE
James Crosby retweeted
Today we are welcoming ASN Neuro to the T&F Neurology journals portfolio! 🥳
spr.ly/6018iDc6p
@ASNeurochem #ASNeuro
James Crosby retweeted
🚨New Supplement🚨
Delighted to announce publication of our latest supplement on #SystemicLupusErythematosus. Click the link below for full access to the articles 👇
bit.ly/3Tq6Rn9
#HEOR #healtheconomics #pharmacoeconomics #healthcare
James Crosby retweeted
The special focus issue on Anticoagulation in Expert Review of Cardiovascular Medicine is now live! 📚
Dive into the latest advancements and perspectives in the world of anticoagulation🩸👇
#CardiovascularMedicine #Anticoagulation #ExpertReview
tandfonline.com/toc/ierk20/2…
James Crosby retweeted
📢New article alert!
I sat down with @drflett to discuss #heartfailure in the UK. He shares his expertise on treatment, cardiac devices and future outlooks...a must-read for anyone interested in #cardiovascular health! 💙
Read the interview for free 👇
tandfonline.com/doi/full/10.…
James Crosby retweeted
Follow @ExpRevVaccines
James Crosby retweeted
📢 2 weeks remaining to submit your application for the Editor-in-Chief position of #ExpertOpiniononOrphanDrugs 📢
We're recruiting for an Editor-in-Chief to lead Expert Opinion on Orphan Drugs, an international journal publishing rigorously peer-reviewed review articles and original papers on #RareDiseases and #OrphanDrugs 💉💊
James Crosby retweeted
Elevated Lipoprotein(a) is the latest variant of ‘bad cholesterol’ found to increase the risk of recurrent coronary heart disease.
Findings, published by @UNSWMedicine researchers in @CMRO_Journal, show it is an important CHD predictor in people 60+⚠️
spr.ly/6014OLHti
James Crosby retweeted
Elevated bloodstream levels of a ‘bad cholesterol’ variant called Lipoprotein(a) have been identified as a risk factor for recurrent coronary heart disease in people aged 60+, in a new longitudinal study led by @UNSW A/Prof. Leon Simons:
newsroom.taylorandfrancisgro…
James Crosby retweeted
🚨 New special issue now online 🚨
Read our latest special issue, which delves further into the different aspects surrounding #Vasculitis. The issue is freely available for everyone to read until next month.
Click here to read the full articles now ➡️ tandfonline.com/toc/ipgm20/1…
James Crosby retweeted
🚨Special issue update🚨
We have released the first article online titled "Advancing towards a worldwide #healthcare system in the post #COVID19 era: benefits and barriers to international collaboration in healthcare".
Available here 👉 bit.ly/3OVXoTX
#Healtheconomics
James Crosby retweeted
Looking forward to heading to Glasgow for #WCP2023 in a months time 💊
Please reach out if you would like to discuss the #ExpertCollection journals, #AcceleratedPublication and/or #PlainLanguageSummaries that Taylor & Francis Group has to offer 👋
wcp2023.org/
James Crosby retweeted
ISPOR 2023, the leading global conference for health economics and outcomes research (#HEOR), May 7-10 at the Boston Convention & Exhibition Center, Boston, MA, USA. Hear the latest hot topics and trends in #HEOR. #ISPORAnnual
Click the link for more 👉 ow.ly/mWGB50Of6m2
James Crosby retweeted
ISPOR 2023, the leading global conference for health economics and outcomes research (#HEOR), May 7-10 at the Boston Convention & Exhibition Center, Boston, MA, USA. Hear the latest hot topics and trends in #HEOR. #ISPORAnnual
click the link for more 👉ow.ly/mWGB50Of6m2
James Crosby retweeted
🚨 How can digital endpoints empower patients? 🚨
WELCOMING SUBMISSIONS at Expert Review of Pharmacoeconomics & Outcomes Research in collaboration with Guest Advisor Katarzyna Kolasa.
👇 Learn more at the link below 👇 #digitalhealth
think.taylorandfrancis.com/i…
James Crosby retweeted
Delighted to share a recent supplement, which has been published in Postgraduate Medicine, on "#Semaglutide for #weight management – an introduction for primary care."
Click here to read the full supplement ➡️ tandfonline.com/toc/ipgm20/1… #WeightManagement #Obesity #PrimaryCare
#RBX2660 a promising treatment for recurrent C.diff has recently gained #FDA approval. This first-in-class microbiota-based live biotherapeutic has huge potential. Drug profile free to read here:tandfonline.com/doi/full/10.…
Editorial free to read here:tandfonline.com/doi/full/10.…
1
65
James Crosby retweeted
We are excited to share this special focus issue on JAK inhibitors in autoimmune and inflammatory diseases in Expert Review of Clinical Immunology #immunology #rheumatology #jakinhibitors
tandfonline.com/toc/ierm20/c…
James Crosby retweeted
To start we would love to know what field you work in to establish who is benefiting most from the 2022 CHEERS statement. Please select one of the options or leave a comment below. #JMECHEERS2022
View the statement here 👉 https://teapawt.net/t.co/s5BHuFrjKx
50%Researcher
33%Editor
17%Peer reviewer
0%Health professional
6 votes • Final results James Crosby retweeted
Discover more about our latest article, economic evaluation of polatuzumab-bendamustine-rituximab vs. tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL, in this interview with the author Dr. Matthias Calamia. #oncology
Click the link for more: https://teapawt.net/t.co/ZbPsiKOgq1



















